Canada Markets closed

Theralase Technologies Inc. (TLT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.14500.0000 (0.00%)
At close: 3:57PM EDT

Theralase Technologies Inc.

41 Hollinger Road
Toronto, ON M4B 3G4
Canada
416 699 5273
http://www.theralase.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Shawn Shirazi B.Sc., M.Sc., Ph.D.Chief Exec. Officer257.01kN/AN/A
Ms. Kristina Hachey C.P.A.CFO & Director305kN/AN/A
Dr. Arkady MandelChief Scientific Officer & Director410kN/AN/A
Mr. David M. Groves B.APres of World Trade DivisionN/AN/AN/A
Mr. Roger John Dumoulin-WhiteDirector of Bus. Devel.N/AN/AN/A
Lori LeachMarketing & Media Relations ConsultantN/AN/AN/A
Mr. Vaughn WyantMarketing & Media Relations ConsultantN/AN/AN/A
Dr. Terry Ruch DVMEquine Medical ConsultantN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. The company is developing TLD-1433, which is in Phase II for the treatment of non-muscle invasive bladder cancer (NMIBC). Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of tissue healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. Theralase Technologies Inc. has a research agreement with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is headquartered in Toronto, Canada.

Corporate Governance

Theralase Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.